Compare Live Nation Entertainment, Inc. (LYV) vs Medtronic PLC (MDT) Price & Performance

Live Nation (LYV) trades at $180.84, up 0.34% today, with bullish technical signals from moving averages despite recent earnings misses. The company reported $25.2B revenue for 2025 with a slim 0.33% net margin, while valuation metrics show elevated P/E (117.49) and P/B (136.72) ratios. Recent news highlights executive share sales and ongoing legal scrutiny, though analyst consensus remains strongly bullish with an $200.20 price target.

Outlook remains mixed with strong revenue growth potential from concert demand and ticketing margins offset by profitability challenges and legal overhangs. The stock offers upside to analyst targets but faces execution risks amid high valuations and recent earnings volatility.

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.